Sign in Register

Drug class

Antiviral-HIV Boosted Protease Inhibitors

Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat. Read more about Antiviral-HIV Boosted Protease Inhibitors

29 drugs in this class 18 manufacturers

Related classes & indications

Antimalarial DrugsAnti-infectives · 223 prescription drugs Antiprotozoal AgentsAnti-infectives · 102 prescription drugs Hiv InfectionTop indication · 274 prescription drugs

Showing 19–27 of 29 drugs

Sort

ATAZANAVIR SULFATE

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

LAURUS LABS LIM

DARUNAVIR

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

DR.REDDY'S LAB

DARUNAVIR

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

AHP

RITONAVIR

ANTIVIRAL-HIV BOOSTED PROTEASE INHIBITORS · HIV INFECTION

AHP

DARUNAVIR

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

AUROBINDO PHARM

DARUNAVIR

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

LUPIN PHARMACEU

DARUNAVIR

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

CIPLA USA, INC.

DARUNAVIR

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

NOVADOZ PHARMAC

DARUNAVIR

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION

VIONA PHARMACEU

Filter & compare in the drug finder → Opens the drug finder with Antiviral-HIV Boosted Protease Inhibitors preselected. Add indication or manufacturer filters there.

About Antiviral-HIV Boosted Protease Inhibitors.

Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat.

The pharmacokinetic booster selectively inhibits cytochrome P450 3A4 enzymes, significantly elevating and prolonging circulating levels of the primary protease inhibitor to prevent the cleavage of viral Gag and Gag-Pol polyproteins into mature, infectious virions.

Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individuals and patients with prior antiretroviral exposure or suspected resistance.

nih.gov
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat
hiv.gov
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individu...
nih.gov
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individu...
fda.gov
The pharmacokinetic booster selectively inhibits cytochrome P450 3A4 enzymes, significantly elevating and prolonging circulating levels of the primary protease inhibitor to prevent the cleavage of viral Gag and Gag-Pol polyproteins into mature, infectious virions
nih.gov
The pharmacokinetic booster selectively inhibits cytochrome P450 3A4 enzymes, significantly elevating and prolonging circulating levels of the primary protease inhibitor to prevent the cleavage of viral Gag and Gag-Pol polyproteins into mature, infectious virions
nih.gov
Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individuals and patients with prior antiretroviral exposure or suspected resistance